Burden of disease study in migraine patients in Japan

Burden of disease study in migraine patients in Japan - BRIDGE-J

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059765

Enrollment

400

Registered

2025-11-13

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.15 years old or more at survey 2.Japan citizen 3.Physician confirmed diagnosis of migraine based on International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria 4.Patients who have given informed consent for participation in this study

Exclusion criteria

Exclusion criteria: 1.Unable to respond to the questionnaire by oneself

Design outcomes

Primary

Measure	Time frame
The proportion of Japanese migraine patients categorized as severe based on Headache Impact Test (HIT-6) (score >=60) by the guideline classification of medical facility (OUG facility or Non-OUG facility)	—

Secondary

Measure	Time frame
The following secondary endpoints will be described by the guideline classification of medical facility (OUG facility or Non-OUG facility): 1.The proportion of Japanese migraine patients categorized as severe based on MIBS-4 (score >=5) 2.The mean HIT-6 score of Japanese migraine patients 3.The mean MIBS-4 score of Japanese migraine patients	—

Countries

Japan

Contacts

Public ContactAbbVie GK Clinical Trial Registration Desk

AbbVie GK NA

abbvie_jpn_info_clingov@abbvie.com03-4577-1111

Outcome results